American Well vs OptimizeRx
AMWL and OPRX side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMWL and OPRX compare
American Well is the larger company, worth 1.4 times as much as OptimizeRx ($200M against $138M).
OptimizeRx grew revenue faster over the last twelve months (−14.0% versus −19.0% for American Well).
OptimizeRx keeps more of each dollar of sales as profit, with a net margin of 5.3% compared with −35.7% at American Well.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMWL | OPRX |
|---|---|---|
| Size and price | ||
| Market cap | $200M | $138M |
| Share price | $11.74 | $7.34 |
| Change, 1 year | 186% | −54.6% |
| Change, 5 years | −92.0% | −89.8% |
| Beta (5Y) | 1.98 | 1.94 |
| Employees | 562 | 104 |
| StockData Score | ||
| Total score | 11 | 11 |
| Valuation score | 3 | 3 |
| Growth score | 2 | 2 |
| Performance score | 1 | 2 (better) |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 28.2× |
| P/S | 0.9× (better) | 1.5× |
| P/B | 0.9× (better) | 1.0× |
| EV/EBITDA | – | 8.2× |
| P/FCF | – | 7.0× |
| FCF yield | −13.2% | 14.4% (better) |
| Fair value | $18.20 | $10.52 |
| Margin of safety | 35.5% (better) | 30.2% |
| Growth | ||
| Revenue growth (TTM) | −19.0% | −14.0% (better) |
| Revenue growth, 5Y average | 0.33% | 20.4% (better) |
| Net income growth (TTM) | – | 14656% |
| Profitability | ||
| Gross margin | 51.9% | 75.3% (better) |
| Operating margin | −37.3% | 12.2% (better) |
| Net margin | −35.7% | 5.3% (better) |
| FCF margin | −12.1% | 21.1% (better) |
| Return on equity | −31.0% | 3.9% (better) |
| Return on invested capital | −145% | 5.5% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.10 (better) |
| Net debt / EBITDA | – | −0.61 |
| Interest coverage | – | 3.1× |
| Current ratio | 2.90 | 5.06 (better) |
| Altman Z-score | −7.14 | 3.39 (better) |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | 0.00% | – |
| Shareholder yield | 0.00% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 42.3% | 59.6% |
| Held by insiders | 15.8% | 19.4% |
| Insider net buying, 12 months | −$1.0M | −$18.8K (better) |
| Short interest, % of float | 1.7% | 7.8% |
Go deeper
- AMWL stock overview
- AMWL income statement
- AMWL valuation and score
- OPRX stock overview
- OPRX income statement
- OPRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.